



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Nasmyth *et al.*

Appl. No. 09/308,109

102(e) Date: June 2, 1999

For: **Methods for Producing the
Anaphase Promoting Complex**

Art Unit: 1634

Examiner: Lu, F.

Atty. Docket: 0652.1880000

Second Supplemental Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed on January 23, 2002. A copy of each document is also provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Second Supplemental Information Disclosure Statement is being filed after the filing of a request for continued examination. No fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Eric K. Steffe
Attorney for Applicants
Registration No. 36,688

Date: 6/4/23

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
SKGF_DC1:163638.2



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0652.1880000/EKS/VSRAPPLICATION NO.
09/308,109APPLICANT
Nasmyth *et al.*102(e) DATE:
June 2, 1999GROUP
1634

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	2002/0028472 A1	03/07/2002	Gmachl, M. <i>et al.</i>	435	7.21	06/29/2001
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM1	WO 98/21236	05/22/1998	WIPO			Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>21</u>	Buschmann, T. <i>et al.</i> , "SUMO-1 Modification of Mdm2 Prevents Its Self-Ubiquitination and Increases Mdm2 Ability to Ubiquitinate p53," <i>Cell</i> 101:753-762, Cell Press (2000).
	AS	<u>21</u>	Gonen, H. <i>et al.</i> , "Identification of the Ubiquitin Carrier Proteins, E2s, Involved in Signal-induced Conjugation and Subsequent Degradation of I κ B α ," <i>J. Biol. Chem.</i> 274:14823-14830, The American Society for Biochemistry and Molecular Biology, Inc. (1999).
	AT	<u>21</u>	Hatfield, P. M. <i>et al.</i> , "Cloning of Ubiquitin Activating Enzyme from Wheat and Expression of a Functional Protein in <i>Escherichia coli</i> ," <i>J. Biol. Chem.</i> 265:15813-15817, The American Society for Biochemistry and Molecular Biology, Inc. (1990).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0652.1880000/EKS/VSAPPLICATION NO.
09/308,109APPLICANT
Nasmyth *et al.*102(e) DATE:
June 2, 1999GROUP
1634

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>22</u>	Lorick, K.L. <i>et al.</i> , "RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination," <i>Proc. Natl. Acad. Sci. USA</i> 96:11364-11369, National Academy Press (1999).
	AS	<u>22</u>	Zachariae, W. and Nasmyth, K. "Whose end is destruction: cell division and the anaphase-promoting complex," <i>Genes Dev.</i> 13:2039-2058, Cold Spring Harbor Laboratory Press (1999).
	AT	<u>22</u>	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.